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Purpose: Dipeptidyl-peptidase-4 (DPP-4) inhibitors are known to increase insulin secretion 
and beta cell proliferation in rodents. To investigate the effects on human beta cells in vivo, 
we utilize immunodeficient mice transplanted with human islets. The study goal was to deter-
mine the efficacy of alogliptin, a DPP-4 inhibitor, to enhance human beta cell function and 
proliferation in an in vivo context using diabetic immunodeficient mice engrafted with human 
pancreatic islets.
Methods: Streptozotocin-induced diabetic NOD-scid IL2rγ null (NSG) mice were transplanted 
with adult human islets in three separate trials. Transplanted mice were treated daily by  gavage 
with alogliptin (30 mg/kg/day) or vehicle control. Islet graft function was compared using 
glucose tolerance tests and non-fasting plasma levels of human insulin and C-peptide; beta cell 
proliferation was determined by bromodeoxyuridine (BrdU) incorporation.
Results: Glucose tolerance tests were significantly improved by alogliptin treatment for mice 
transplanted with islets from two of the three human islet donors. Islet-engrafted mice treated 
with alogliptin also had significantly higher plasma levels of human insulin and C-peptide 
compared to vehicle controls. The percentage of insulin+BrdU+ cells in human islet grafts 
from alogliptin-treated mice was approximately 10-fold more than from vehicle control mice, 
consistent with a significant increase in human beta cell proliferation.
Conclusion: Human islet-engrafted immunodeficient mice treated with alogliptin show 
improved human insulin secretion and beta cell proliferation compared to control mice engrafted 
with the same donor islets. Immunodeficient mice transplanted with human islets provide a useful 
model to interrogate potential therapies to improve human islet function and survival in vivo.
Keywords: human islet transplant, DPP-4 inhibitor, glucose tolerance, plasma insulin
Introduction
Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists increase glucose-
dependent insulin secretion, beta cell viability, and activate proliferative pathways 
that lead to increased beta cell mass in rodents.1,2 In clinical trials with type 2 diabetic 
patients, GLP-1 receptor agonists lowered both fasting and postprandial glucose 
concentrations,3,4 although no improvement (as measured by C-peptide secretion) 
was observed in patients with long-standing type 1 diabetes.5 Glycemic control of 
patients taking metformin or sulfonylurea was also improved in conjunction with 
GLP-1 receptor agonists.6–8 In clinical trials with agents that block GLP-1 degrada-
tion, such as dipeptidyl-peptidase-4 (DPP-4) inhibitors, fasting and postprandial 





glucose levels of patients are also lowered, consistent 
with improved pancreatic beta cell function.9–11 However, 
human islet function remains difficult to assess directly 
due to inaccessibility of relevant tissues, as well as inher-
ent variability between patients. An alternative method to 
investigate human islet function in vivo is to transplant 
human islets into streptozotocin (STZ)-induced diabetic 
NOD-scid IL2rγ null (NSG) mice.12,13
Recently, a new DPP-4 inhibitor, alogliptin, has been 
developed14 and its safety and efficacy in treating type 2 dia-
betes (T2D) patients is being investigated.15–17 Alogliptin was 
found to improve glycemic control in patients with poorly 
controlled diabetes as evidenced by reduced fasting blood 
glucose and hemoglobin A1c levels.17 We hypothesized 
that alogliptin treatment of diabetic immunodeficient mice 
engrafted with human islets will measurably enhance the 
proliferation and insulin secretory function of human beta 
cells in an in vivo setting. The goal of this study was to utilize 
STZ-induced diabetic NSG mice transplanted with human 
pancreatic islets to determine the ability of alogliptin to 
enhance human beta cell function and proliferation.
Material and methods
Mice and diabetes induction
NOD.cg-PrkdcscidIl2rgtm1Wjl/SzJ (abbreviated as NOD-scid 
IL2rγ  null or NSG) mice from The Jackson Laboratory (Bar 
Harbor, ME, USA) were housed in a specific pathogen-free 
facility and maintained12 in accordance with the Institu-
tional Animal Care and Use Committee of the University of 
 Massachusetts Medical School; the NSG is an immunode-
ficient mouse that can be engrafted with functional human 
cells and tissues for in vivo studies.18
Male NSG mice (8–12 weeks old) received a single 
intraperitoneal injection of 160 mg/kg STZ (Sigma-
Aldrich, St Louis, MI, USA) to induce diabetes (blood 
glucose .300 mg/dL on two consecutive days). Blood glu-
cose was monitored with an ACCU-CHEK Aviva Plus glu-
cometer (Roche Diagnostics, Indianapolis, IL, USA). After 
diabetes was confirmed, mice were given insulin implants 
(LinShin Canada, Inc, Toronto, ON, Canada) until human 
islets were available for transplant.
human islet transplantation
Human islets were obtained from the Integrated Islet Distri-
bution Program under protocols approved by the Institutional 
Review Board of the University of Massachusetts Medical 
School. Insulin implants were removed upon transplant of 
2000 human islet equivalents (IEQs). Briefly, the mice were 
anesthetized and prepared for surgery. The skin and muscle 
layer over the spleen was incised, and the kidney was gently 
externalized with forceps. The human islets (suspended in 
Connaught Medical Research Laboratories plus 1% fetal 
bovine serum [FBS]) were injected into the subrenal cap-
sular space using a SURFLO winged infusion set (23 g × 
3/4 inch; Terumo Medical Corporation, Somerset, NJ, USA). 
The kidney was then replaced in the abdominal cavity, the 
muscle was sutured, and the skin was closed with an Autoclip 
wound closure system (Thermo Fisher Scientific, Houston, 
TX, USA).
alogliptin treatment
One day post-transplant, diabetic mice that received islets 
from a single donor were randomized into two groups of five 
mice each and treated daily by oral gavage with 30 mg/kg/day 
alogliptin (provided by Takeda Pharmaceuticals North 
America, Deerfield, IL, USA) or equivalent volume of 
vehicle (phosphate-buffered saline [PBS]). The 30 mg/kg/day 
dosage is mid-range between doses (15 and 45 mg/kg) that 
have previously been shown to be effective in restoring beta 
cell mass and islet function in two different mouse models 
of diabetes.19,20 Daily treatments were continued until graft 
removal at 32–39 days post-transplant.
glucose tolerance test
Mice were fasted overnight and blood glucose was measured 
following intraperitoneal injection of glucose (2.0 g/kg body 
weight). Glucose area under the curve (AUC) was calculated 
by the trapezoidal rule.
Human insulin and C-peptide analysis
Heparinized blood from nonfasting mice was collected with 
protease inhibitor (aprotinin; Sigma-Aldrich) at 3–4 weeks 
post-transplant; plasma was stored at −80°C until analyzed 
by human-specific enzyme-linked immunosorbent assay 
(ELISA; ALPCO Diagnostics, Salem, NH, USA).
Bromodeoxyuridine treatment, histology, 
and immunofluorescence staining
Human islet-engrafted mice were provided drinking water 
containing 0.8 mg/mL of bromodeoxyuridine (BrdU) ad 
libitum for 7 days prior to recovery of the graft-bearing 
kidney. Islet graft-bearing kidneys were fixed in 10% neutral-
buffered formalin. Paraffin-embedded sections were dual-
stained with guinea pig anti-insulin (Dako, Carpinteria, CA, 
USA) and rat anti-BrdU (Accurate Chemical, Westbury, NJ, 
USA); secondary Alexa-Fluor and Cy-5 antibodies and 4′,6-
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diamidino-2-phenylindole (DAPI) were from  Sigma-Aldrich. 
Insulin+ and insulin+BrdU+ cells were visualized by fluo-
rescence microscopy (Zeiss, New York, NY, USA); counts 
were performed with MetaMorph (Molecular Devices, 
Downington, PA, USA).
Statistical analyses
Time-course data were analyzed by repeated measures 
analysis of variances (ANOVA) with Bonferroni post-hoc 
test; remaining data were analyzed with Mann-Whitney or 
t-test as appropriate (GraphPad Prism, San Diego, CA, USA). 
P-values ,0.05 were considered significant.
Results
Normoglycemic NSG mice (blood glucose ,150 mg/dL) 
were made chemically diabetic with STZ treatment. After 
diabetes was confirmed, mice were given subcutaneous 
insulin implants to maintain the health of the animals until 
human islets were available for transplant. Three indepen-
dent studies were performed with human islets from three 
different donors. The islet donor characteristics are shown 
in Table 1. Daily alogliptin (or vehicle control) treatments 
were started at day 1 post-transplant. Normoglycemia was 
restored within 1 week for diabetic mice transplanted with 
2000 IEQs from both Donors 1 and 2, regardless of treat-
ment status (Figure 1A). In contrast, mice transplanted with 
2000 IEQs from Donor 3 and treated with alogliptin showed 
a significant acceleration in the lowering of blood glucose 
levels relative to mice receiving vehicle alone. At the end of 
the study period, all mice in all groups were normoglycemic. 
As expected, the body weights (Figure 1B) of alogliptin-
treated mice transplanted with Donor 3 islets significantly 
improved compared to the vehicle control mice.
Daily alogliptin treatment also significantly improved 
glucose tolerance tests (GTTs) in mice engrafted with islets 
from two of the three human donors (Figure 2A); this was also 
demonstrated with glucose AUC measurements (Figure 2B). 
Consistent with improved GTTs, the non-fasting plasma levels 
of both human insulin (Figure 3A) and C-peptide (Figure 3B) 
were significantly higher in islet-engrafted mice treated with 
alogliptin compared to vehicle-treated mice. When  comparing 
individual donors, human insulin and C-peptide values fol-
lowing alogliptin treatment were similar between Donors 2 
and 3, consistent with the recipient mice blood glucose levels 
(mean =89 and 82 mg/dL, respectively) obtained at the time 
of analysis. Interestingly, although blood glucose levels were 
higher in control mice engrafted with islets from Donor 3 
(mean =198 mg/dL) than from Donor 2 (mean =87 mg/dL), 
human insulin values from Donor 3 engrafted mice were 
somewhat elevated compared to Donor 2 (Figure 3A), whereas 
C-peptide levels were similar (Figure 3B).
To determine whether alogliptin treatment enhances beta 
cell proliferation within the human islet grafts, the mice were 
supplied with BrdU in their drinking water. Upon surgical 
removal of the graft-bearing kidney all mice became acutely 
hyperglycemic (blood glucose .500 mg/dL), thus document-
ing that the human islet graft was responsible for maintaining 
normoglycemia. The recovered islet grafts were subsequently 
immunostained for insulin and BrdU.  Immunofluorescent 
analysis of human islet grafts from all three donors dem-
onstrated that the percentage of insulin+BrdU+ cells from 
alogliptin-treated mice was significantly higher than from 
vehicle control mice (Figure 4). Representative islet graft sec-
tions from a vehicle control and an alogliptin-treated mouse 
engrafted with islets from Donor 1 are shown in Figure 5A 
and B, respectively. Although BrdU+ staining indicative of 
proliferating cells was readily detectable in all islet graft sec-
tions (Figure 5A), only two of six human islet grafts analyzed 
from control mice (one each from Donors 1 and 3) had any 
detectable insulin+BrdU+ cells. In contrast, insulin+BrdU+ 
cells (Figure 5B) were present in five of six islet grafts ana-
lyzed (from all three human islet donors) in alogliptin-treated 
mice. When totaled, the average proliferation of human beta 
cells in all islet grafts analyzed from alogliptin-treated mice 
was 0.58% (44 of 7591 insulin+ cells), a 10-fold increase 
from that observed in islet grafts from vehicle control mice 
(0.056%, 2 of 3542 insulin+ cells).
Discussion
This study investigated the therapeutic efficacy of alogliptin, 
a DPP-4 inhibitor, on human beta cell function and prolif-
eration in diabetic immunodeficient NSG mice engrafted 
with adult human islets. Because multiple cohorts of mice 
can be transplanted with islets from a single human donor, 
donor-specific beta cell function can be compared directly 
in islet-engrafted control and treated mice, thus eliminating 
variability in donor-to-donor islet isolation and handling, 
as well as differences due to age, sex, body mass index 
Table 1 Demographic characteristics of human islet donors
Donor 1 Donor 2 Donor 3
age, years 51 53 65
Sex (M/F) F nr M
Body weight, kg 69.0 nr nr
BMi, kg/m2 23.9 27.3 24.5
Abbreviations: BMi, body mass index; F, female; M, male; nr, not recorded.
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Figure 1 Comparison of blood glucose and body weights of control and alogliptin-treated mice engrafted with human islets.
Notes: Diabetic nSg mice were transplanted with human islets from three individual donors and treated daily by gavage with alogliptin (n=5, each donor) or vehicle control 
(n=5, each donor). (A) Blood glucose and (B) body weight of the mice were monitored over the treatment period on the days indicated; shown are mean ± standard error 
of the mean. *P<0.05.



































































































Figure 2 Comparison of glucose tolerance tests in control and alogliptin-treated mice engrafted with human islets.
Notes: human islet engrafted mice were treated daily with alogliptin or vehicle control. (A) a glucose tolerance test was administered to mice engrafted with islets from 
Donors 1 and 2 at days 21 and 19, respectively, following islet transplantation. The glucose tolerance test on mice engrafted with Donor 3 islets was administered at day 31 
when the blood glucose of vehicle control mice was approaching normoglycemia. *P<0.05. (B) glucose aUc for the 120 min glucose tolerance test shown in (A); n=4 mice 
per group for each donor; shown are mean ± standard error of the mean.
Abbreviations: AUC, area under the curve; NS, not significant.















































Figure 3 Comparison of human insulin and C-peptide levels in control and alogliptin-treated mice engrafted with human islets.
Notes: Non-fasting blood was collected from NSG mice engrafted with human islets from Donors 2 and 3 on days 26 and 24, respectively, following transplant. Plasma levels 
of (A) human insulin and (B) human C-peptide from individual vehicle control (n=8 total, 4 per islet donor) or alogliptin-treated (n=7 total, 4 from Donor 2, and 3 from 
Donor 3) mice are shown. Plasma samples from mice engrafted with islets from Donor 1 were not available for analysis. each dot or triangle represents data obtained from 
an individual mouse engrafted with human islets from Donors 2 or 3, respectively; horizontal bar indicates the mean for each group.






















Figure 4 induction of human beta cell proliferation with alogliptin treatment of 
islet engrafted mice. Percent human beta cell proliferation in islet grafts from vehicle 
control (n=6 total, 2 per islet donor) and alogliptin-treated (n=6 total) mice.




Figure 5 insulin+BrdU+ beta cells in human islet grafts from alogliptin-treated mice.
Notes: representative micrographs of human islets from a single donor (Donor 1) 
engrafted in (A) vehicle control or (B) alogliptin-treated mice are shown. Top 
panels show insulin (red) and BrdU (green) staining; bottom panels include nuclei 
staining with DaPi (blue). Similar results were seen with islet grafts from Donors 
2 and 3. arrows show insulin+BrdU+ cells; arrowheads indicate insulin-negative 
BrdU+ cells; cells were only counted as insulin+ if the staining was visible around the 
entire perimeter of the nucleus.
Abbreviations: BrdU, bromodeoxyuridine; DaPi, 4′,6-diamidino-2-phenylindole.
(BMI), lifestyle, or pre-existing disease. In this study, we 
utilized human islets derived from both male and female 
islet donors, aged 51–65 years, with BMI between 24–28. 
Here we report significant beneficial effects of alogliptin on 
human beta cell proliferation, circulating levels of human 
insulin and C-peptide, and glucose homeostasis of NSG mice 
transplanted with adult human islets.
A recent study in a mouse model of diabetes demonstrated 
similar beneficial effects of alogliptin to lower fasting and 
postprandial blood glucose levels in diabetic mice.19 This 
study also demonstrated an improvement in beta cell mass 
and insulin content in pancreata of alogliptin-treated mice.19 
Recently, alogliptin in combination with pioglitazone has been 
reported to enhance regeneration of transplanted syngeneic 
mouse islets and endogenous islets of STZ-diabetic mice.20 
Although informative, such studies on mouse beta cells may 
not accurately predict human beta cell responses due to dif-
ferences in the architecture, signaling pathways, and relative 
proportions of endocrine cells, as well as beta cell proliferative 
capacity which is robust in young rodents but negligible in 
humans, especially in individuals .30 years old.21,22
To circumvent potential discrepancies in therapeutic 
outcome due to species differences, we utilized diabetic NSG 
mice engrafted with human islets. We observed improved 





glucose tolerance tests in alogliptin-treated versus control 
mice transplanted with human islets from two of three indi-
vidual donors (including 65-year-old Donor 3). Because 
our immunodeficient mice are exposed to the same diet and 
housing conditions, we can effectively exclude the potential 
contribution of such factors to glucose homeostasis and 
suggest that alogliptin treatment directly enhances human 
islet function.
Indeed, the improved glucose tolerance in human islet 
engrafted mice treated with alogliptin is consistent with our 
finding that plasma levels of human insulin and C-peptide 
were also significantly increased in these alogliptin-treated 
mice. We observed a 1.5-fold increase in human insulin 
(742±106 versus 483±91 pg/mL) and a 1.8-fold increase 
in human C-peptide (2.17±0.47 versus 1.18±0.22 ng/mL) 
in alogliptin-treated versus control mice. This is strikingly 
consistent with data from obese diabetic ob/ob mice, where 
4 weeks of treatment with alogliptin increased plasma insulin 
by 1.5–2.0 fold.23 Similar results were also reported in T2D 
patients, in whom the homeostasis model assessment of 
beta-cell function (HOMA-B) worsened with placebo, but 
improved with alogliptin treatment.17
In rodents, DPP-4 inhibitors were reported to increase the 
proliferation of beta cells.1,2,24 In our study, alogliptin treat-
ment also stimulated human beta cell proliferation within the 
islet grafts by approximately 10-fold, a similar magnitude 
of induction that we and others have reported for engrafted 
human beta cells in response to hyperglycemia.25,26 Together 
these data may suggest that human beta cells, even from older 
individuals, can be induced to proliferate in vivo in response 
to certain inductive stimuli, albeit at a much lower level 
than observed in rodents. Nonetheless, the small numbers 
of proliferating beta cells cannot account for the significant 
increase in plasma levels of human insulin and improved 
glucose tolerance tests we observed. Speculatively, however, 
longer-term alogliptin treatment in patients with T2D may 
result in a small, but functionally relevant enhancement of 
human beta cell mass that may add to other ameliorative 
effects of alogliptin on islet function and survival to improve 
the total therapeutic benefit.
Conclusion
In this study we demonstrate that human islet-engrafted 
NSG mice treated with alogliptin show improved glucose 
tolerance and increased human insulin secretion and beta 
cell proliferation compared to islet-engrafted control mice. 
Thus, immunodeficient mice transplanted with human islets 
provide a useful model to interrogate potential therapies to 
improve human islet function and survival in an in vivo set-
ting without putting patients at risk. In addition, the ability 
to transplant multiple mice with human islets from a single 
donor provides a powerful experimental paradigm to assess 
potential mechanisms at play, which is limited in clinical 
studies with human patients.
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